Valeant Pharmaceuticals Intl Inc (VRX.TO) 134.45 $VRX.TO
30-Year Ultra Long Gilt Futures Updates, Partnerships, Notes Offer Pricings, and Drug Approvals - Analyst Notes on IntercontinentalExchange, Western Union, Essex Property , Valeant and Pharmacyclics
PR Newswire - Tue Apr 15, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding IntercontinentalExchange, Inc. (NYSE: ICE), The Western Union Company (NYSE: WU), Essex Property Trust Inc. (NYSE: ESS), Valeant Pharmaceuticals International, Inc. (NYSE: VRX) and Pharmacyclics Inc. (NASDAQ: PCYC). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1135-100free.
Favourable Rulings, Topline Results, Earnings Schedules, Approvals, and New Advisory Boards - Analyst Notes on Lilly, UnitedHealth Group, Valeant, Forest Laboratories, and Zoetis
PR Newswire - Fri Apr 11, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Eli Lilly & Co. (NYSE: LLY), UnitedHealth Group, Inc. (NYSE: UNH), Valeant Pharmaceuticals International, Inc. (NYSE: VRX), Forest Laboratories Inc. (NYSE: FRX), and Zoetis Inc. (NYSE: ZTS). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Global Pain Management Drugs Market 2014-2018 with Abbott Labs, Eli Lilly, Endo Health Solutions, Pfizer & Purdue Pharma Dominating
M2 - Fri Apr 11, 4:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bjv7jj/global_pain) has announced the addition of the "Global Pain Management Drugs Market 2014-2018 with Abbott Labs, Eli Lilly, Endo health Solutions, Pfizer & Purdue Pharma Dominating" report to their offering. The Global Pain Management Drugs market will grow at a CAGR of 3.84 percent over the period 2013-2018. One of the main drivers in this market is the increase in global aging population. The rise in aging population has consequently led to an increase in the incidence of diseases such as chronic arthritis, diabetic neuropathy, osteoarthritis, and cancer. R&D activities are increasing due to the strong need for new efficacious and better-tolerated medications. Developing better pain treatments is the main goal of all pain research being conducted by various institutes. Morphine is one such drug that works through the body's natural pain-killing machinery, preventing pain messages from reaching the brain. Patients receiving morphine also face the problem of morphine tolerance. Scientists are working toward the development of a morphine-like drug that will have the pain-deadening qualities of morphine but without the drug's negative side effects, such as sedation and the potential for addiction. Further, the report states that one of the main challenges is the increase in generic competition. The patent expiry of a drug results in the loss of the exclusive market for that drug, leading to a rapid decline in sales. The key vendors dominating this space are: - Abbott Laboratories - Eli Lilly and Co. - Endo Health Solutions Inc. - Pfizer Inc. - Purdue Pharma L.P. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Market Segmentation by Category - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis Other Companies Featured: - Actavis plc - Allergen Inc. - Astra Zenca plc - Baxter International Inc. - Bayer Healthcare AG - Boehringer Ingelheim GmbH - Boston Scientific Corp. - Bristol Myers Squibb Co. - Durect Corp. - F. Hoffmann La Roche Ltd. - Forest Laboratories Inc. - GlaxoSmithKline plc - Hospira Inc. - Johnson & Johnson - Merck & Co. Inc. - Novartis AG - Pain Therapeutics Inc. - Sanofi S.A. - St. Jude Medical Inc. - UCB S.A. - Valeant Pharmaceuticals International Inc. - Zalicus Inc. For more information visit http://www.researchandmarkets.com/research/bj...lobal_pain
Health Care Stocks Technical Coverage -- Research on Valeant Pharma Intl., Alkermes, Delcath Systems, and Acura Pharma
PR Newswire - Wed Apr 09, 7:35AM CDT
On Tuesday, April 08, 2014, the NASDAQ Composite ended at 4,112.99, up 0.81%, the Dow Jones Industrial Average edged 0.06% higher to finish the day at 16,256.14, and the S&P 500 closed at 1,851.96, up 0.38%. The gains were broad based as seven out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index finished the day at 659.34, down 0.80%, and the same has fallen by 3.36% in the previous three trading sessions. Investor-Edge has initiated coverage on the following equities: Valeant Pharmaceuticals International Inc. (NYSE: VRX), Alkermes PLC (NASDAQ: ALKS), Delcath Systems Inc. (NASDAQ: DCTH) and Acura Pharmaceuticals Inc. (NASDAQ: ACUR). Free technical research on VRX, ALKS, DCTH and ACUR can be downloaded upon signing up at:
Drug Recommendations, Legal Updates, Awards, Stock Price Movements, and Upcoming Results and Conference Call Schedules - Analyst Notes on MannKind, Mylan, WellPoint, Valeant, and Forest Laboratories
PR Newswire - Mon Apr 07, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding MannKind Corporation (NASDAQ: MNKD), Mylan Inc. (NASDAQ: MYL), WellPoint Inc. (NYSE: WLP), Valeant Pharmaceuticals International Inc. (NYSE: VRX), and Forest Laboratories Inc. (NYSE: FRX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Actavis & Valeant Pharmaceuticals International partnership awarded US FDA's approval for Metronidazole 1.3% Vaginal Gel's NDA for the treatment of bacterial vaginosis
M2 - Wed Mar 26, 3:06AM CDT
Pharmaceutical company Actavis (NYSE:ACT) and Valeant Pharmaceuticals International (NYSE:VRX) on Tuesday jointly announced US Food and Drug Administration's (FDA) approval for the New Drug Application (NDA) for the antibiotic Metronidazole 1.3% Vaginal Gel for the treatment of bacterial vaginosis (BV).
Actavis and Valeant Announce FDA Approval for Metronidazole 1.3%
PR Newswire - Tue Mar 25, 4:00PM CDT
Actavis plc (NYSE: ACT) and Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Metronidazole 1.3% Vaginal Gel, an antibiotic for the treatment of bacterial vaginosis (BV). Actavis acquired the rights to Metronidazole 1.3% from Valeant Pharmaceuticals International in April 2013.
Reviewing the Top Health Care Equities -- Research on IntelliPharmaCeutics, Delcath Systems, Valeant Pharma and Alkermes
PR Newswire - Fri Mar 21, 4:39PM CDT
On Thursday, March 20, 2014, the NASDAQ Composite ended at 4,319.29, up 0.27%, the Dow Jones Industrial Average gained 0.67% to reach 16,331.05, and the S&P 500 closed at 1,872.01, up 0.60%. The gains were broad based as nine of ten sectors finished higher. The S&P 500 Health Care Sector Index finished the day 0.02% lower at 686.29, whereas, the index has advanced 0.77% in the last one month. Investor-Edge has initiated coverage on the following equities: IntelliPharmaCeutics International Inc. (NASDAQ: IPCI), Delcath Systems Inc. (NASDAQ: DCTH), Valeant Pharmaceuticals International Inc. (NYSE: VRX) and Alkermes PLC (NASDAQ: ALKS). Free technical research on IPCI, DCTH, VRX and ALKS can be downloaded upon signing up at:
Valeant Pharmaceuticals Reports Fourth Quarter And Full Year 2013 Financial Results
CNW Group - Thu Feb 27, 5:02AM CST
Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) announces fourth quarter financial results for 2013.
Access Midstream Partners Posts Financial Results for the 2013 Fourth Quarter and Full Year
Close-Up Media - Thu Feb 20, 11:31PM CST
Access Midstream Partners, L.P. announced financial results for the 2013 fourth quarter and full year. The Partnership's adjusted EBITDA for the 2013 fourth quarter totaled $240.6 million, an increase of $121.6 million, or 102.2 percent, from 2012 fourth quarter adjusted EBITDA of $119.0 million.
Valeant Pharmaceuticals To Announce 2013 Fourth Quarter And Full Year Results On February 27, 2014
CNW Group - Wed Feb 05, 4:01PM CST
Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that it will host a conference call and a live Internet webcast along with a slide presentation on Thursday, February 27, 2014 at 8:00 a.m. ET (5:00 a.m. PT) to discuss results for the 2013 fourth quarter and full year.
Valeant Pharmaceuticals International to purchase PreCision Dermatology
M2 - Tue Feb 04, 7:09AM CST
Specialist pharmaceutical company Valeant Pharmaceuticals International Inc (NYSE:VRX)(TSX:VRX), based in Canada, reported on Monday the execution of a definitive agreement to acquire PreCision Dermatology Inc for USD475m in cash.
Concise Analysis of the International Fuel Assemblies for the Nuclear Power Industry - Forecasts to 2020
M2 - Tue Feb 04, 4:13AM CST
Research and Markets (http://www.researchandmarkets.com/research/c6bjcs/fuel_assemblies) has announced the addition of the "Concise Analysis of the International Fuel Assemblies for the Nuclear Power Industry - Forecasts to 2020" report to their offering. "Concise Analysis of the International Fuel Assemblies for the Nuclear Power Industry - Forecasts to 2020", analyzes the market for nuclear fuel assemblies used in commercial nuclear reactors and provides in-depth analysis of the demand in three major regions of the world, including key countries and emerging nuclear nations. The fuel assemblies market analysis provides insights on uranium, conversion, enrichment and fabrication markets. The geographical market analysis is achieved through the division of the global market into three major regions: North America, Europe and Asia-Pacific. Scope - Analysis of the growth of the global nuclear industry and the demand for Fuel Assemblies in various key regions, including Europe, Asia-Pacific and North America. - Analysis of trends in the global nuclear power sector and opportunities in the front end nuclear fuel cycle market. - Nuclear fuel assembly, uranium, conversion, enrichment and fabrication market sizes from 2006 to 2012 and forecast up to 2020 - In-depth analysis and forecasts of the growth potential of the front end nuclear fuel cycle market up to 2020 Reasons to buy - Gain up to date information and analysis relating to global market size of key front-end activities in nuclear fuel cycle - Identify key regions representing potential growth opportunities for the nuclear fuel market - Understand drivers and restraints of front-end activities in nuclear fuel cycle in key countries - Gain information about major players involved in the front end activities of the nuclear fuel cycle industry - Understand potential market opportunities in various geographies and fine tune your business strategy in target locations Key Topics Covered: 1 Table of Contents 2 Introduction 3 Global Fuel Assembly Market Analysis, 2006-2020 4 Fuel Assembly Market Analysis, Europe, 2006-2020 5 Fuel Assembly Market Analysis, North America, 2006-2020 6 Fuel Assembly Market Analysis, Asia-Pacific, 2006-2020 7 Fuel Assembly Market Analysis, Emerging Nuclear Countries, 2006-2020 8 Appendix For more information visit http://www.researchandmarkets.com/research/c6...assemblies
Valeant buying PreCision Dermatology for $475M
AP - Mon Feb 03, 10:05AM CST
NEW YORK (AP) — Valeant Pharmaceuticals is looking to expand its skin care business by buying PreCision Dermatology for $475 million.
Valeant Pharmaceuticals to Acquire Precision Dermatology for $475 Million
CNW Group - Mon Feb 03, 7:01AM CST
Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) today announced that it has entered into a definitive agreement under which Valeant will acquire PreCision Dermatology, Inc. for $475 million in cash, plus an additional $25 million payable upon the achievement of a sales-based milestone. PreCision develops and markets high quality dermatology products with leading products such as Locoid, Hylatopic, Clindagel, and BenzEFoam. PreCision expects to have approximately $130 million in revenue in 2014. The transaction is expected to close in the first half of 2014 and Valeant expects the transaction, once completed, to be immediately accretive to Valeant's cash earnings per share.
30-Year Ultra Long Gilt Futures Updates, Partnerships, Notes Offer Pricings, and Drug Approvals - Analyst Notes on IntercontinentalExchange, Western Union, Essex Property , Valeant and Pharmacyclics
PR Newswire - Tue Apr 15, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding IntercontinentalExchange, Inc. (NYSE: ICE), The Western Union Company (NYSE: WU), Essex Property Trust Inc. (NYSE: ESS), Valeant Pharmaceuticals International, Inc. (NYSE: VRX) and Pharmacyclics Inc. (NASDAQ: PCYC). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1135-100free.
Favourable Rulings, Topline Results, Earnings Schedules, Approvals, and New Advisory Boards - Analyst Notes on Lilly, UnitedHealth Group, Valeant, Forest Laboratories, and Zoetis
PR Newswire - Fri Apr 11, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Eli Lilly & Co. (NYSE: LLY), UnitedHealth Group, Inc. (NYSE: UNH), Valeant Pharmaceuticals International, Inc. (NYSE: VRX), Forest Laboratories Inc. (NYSE: FRX), and Zoetis Inc. (NYSE: ZTS). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Global Pain Management Drugs Market 2014-2018 with Abbott Labs, Eli Lilly, Endo Health Solutions, Pfizer & Purdue Pharma Dominating
M2 - Fri Apr 11, 4:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bjv7jj/global_pain) has announced the addition of the "Global Pain Management Drugs Market 2014-2018 with Abbott Labs, Eli Lilly, Endo health Solutions, Pfizer & Purdue Pharma Dominating" report to their offering. The Global Pain Management Drugs market will grow at a CAGR of 3.84 percent over the period 2013-2018. One of the main drivers in this market is the increase in global aging population. The rise in aging population has consequently led to an increase in the incidence of diseases such as chronic arthritis, diabetic neuropathy, osteoarthritis, and cancer. R&D activities are increasing due to the strong need for new efficacious and better-tolerated medications. Developing better pain treatments is the main goal of all pain research being conducted by various institutes. Morphine is one such drug that works through the body's natural pain-killing machinery, preventing pain messages from reaching the brain. Patients receiving morphine also face the problem of morphine tolerance. Scientists are working toward the development of a morphine-like drug that will have the pain-deadening qualities of morphine but without the drug's negative side effects, such as sedation and the potential for addiction. Further, the report states that one of the main challenges is the increase in generic competition. The patent expiry of a drug results in the loss of the exclusive market for that drug, leading to a rapid decline in sales. The key vendors dominating this space are: - Abbott Laboratories - Eli Lilly and Co. - Endo Health Solutions Inc. - Pfizer Inc. - Purdue Pharma L.P. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Market Segmentation by Category - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis Other Companies Featured: - Actavis plc - Allergen Inc. - Astra Zenca plc - Baxter International Inc. - Bayer Healthcare AG - Boehringer Ingelheim GmbH - Boston Scientific Corp. - Bristol Myers Squibb Co. - Durect Corp. - F. Hoffmann La Roche Ltd. - Forest Laboratories Inc. - GlaxoSmithKline plc - Hospira Inc. - Johnson & Johnson - Merck & Co. Inc. - Novartis AG - Pain Therapeutics Inc. - Sanofi S.A. - St. Jude Medical Inc. - UCB S.A. - Valeant Pharmaceuticals International Inc. - Zalicus Inc. For more information visit http://www.researchandmarkets.com/research/bj...lobal_pain
Health Care Stocks Technical Coverage -- Research on Valeant Pharma Intl., Alkermes, Delcath Systems, and Acura Pharma
PR Newswire - Wed Apr 09, 7:35AM CDT
On Tuesday, April 08, 2014, the NASDAQ Composite ended at 4,112.99, up 0.81%, the Dow Jones Industrial Average edged 0.06% higher to finish the day at 16,256.14, and the S&P 500 closed at 1,851.96, up 0.38%. The gains were broad based as seven out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index finished the day at 659.34, down 0.80%, and the same has fallen by 3.36% in the previous three trading sessions. Investor-Edge has initiated coverage on the following equities: Valeant Pharmaceuticals International Inc. (NYSE: VRX), Alkermes PLC (NASDAQ: ALKS), Delcath Systems Inc. (NASDAQ: DCTH) and Acura Pharmaceuticals Inc. (NASDAQ: ACUR). Free technical research on VRX, ALKS, DCTH and ACUR can be downloaded upon signing up at:
Drug Recommendations, Legal Updates, Awards, Stock Price Movements, and Upcoming Results and Conference Call Schedules - Analyst Notes on MannKind, Mylan, WellPoint, Valeant, and Forest Laboratories
PR Newswire - Mon Apr 07, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding MannKind Corporation (NASDAQ: MNKD), Mylan Inc. (NASDAQ: MYL), WellPoint Inc. (NYSE: WLP), Valeant Pharmaceuticals International Inc. (NYSE: VRX), and Forest Laboratories Inc. (NYSE: FRX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Actavis & Valeant Pharmaceuticals International partnership awarded US FDA's approval for Metronidazole 1.3% Vaginal Gel's NDA for the treatment of bacterial vaginosis
M2 - Wed Mar 26, 3:06AM CDT
Pharmaceutical company Actavis (NYSE:ACT) and Valeant Pharmaceuticals International (NYSE:VRX) on Tuesday jointly announced US Food and Drug Administration's (FDA) approval for the New Drug Application (NDA) for the antibiotic Metronidazole 1.3% Vaginal Gel for the treatment of bacterial vaginosis (BV).
Actavis and Valeant Announce FDA Approval for Metronidazole 1.3%
PR Newswire - Tue Mar 25, 4:00PM CDT
Actavis plc (NYSE: ACT) and Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Metronidazole 1.3% Vaginal Gel, an antibiotic for the treatment of bacterial vaginosis (BV). Actavis acquired the rights to Metronidazole 1.3% from Valeant Pharmaceuticals International in April 2013.
Reviewing the Top Health Care Equities -- Research on IntelliPharmaCeutics, Delcath Systems, Valeant Pharma and Alkermes
PR Newswire - Fri Mar 21, 4:39PM CDT
On Thursday, March 20, 2014, the NASDAQ Composite ended at 4,319.29, up 0.27%, the Dow Jones Industrial Average gained 0.67% to reach 16,331.05, and the S&P 500 closed at 1,872.01, up 0.60%. The gains were broad based as nine of ten sectors finished higher. The S&P 500 Health Care Sector Index finished the day 0.02% lower at 686.29, whereas, the index has advanced 0.77% in the last one month. Investor-Edge has initiated coverage on the following equities: IntelliPharmaCeutics International Inc. (NASDAQ: IPCI), Delcath Systems Inc. (NASDAQ: DCTH), Valeant Pharmaceuticals International Inc. (NYSE: VRX) and Alkermes PLC (NASDAQ: ALKS). Free technical research on IPCI, DCTH, VRX and ALKS can be downloaded upon signing up at:
Valeant Pharmaceuticals Reports Fourth Quarter And Full Year 2013 Financial Results
CNW Group - Thu Feb 27, 5:02AM CST
Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) announces fourth quarter financial results for 2013.
Access Midstream Partners Posts Financial Results for the 2013 Fourth Quarter and Full Year
Close-Up Media - Thu Feb 20, 11:31PM CST
Access Midstream Partners, L.P. announced financial results for the 2013 fourth quarter and full year. The Partnership's adjusted EBITDA for the 2013 fourth quarter totaled $240.6 million, an increase of $121.6 million, or 102.2 percent, from 2012 fourth quarter adjusted EBITDA of $119.0 million.
Valeant Pharmaceuticals To Announce 2013 Fourth Quarter And Full Year Results On February 27, 2014
CNW Group - Wed Feb 05, 4:01PM CST
Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that it will host a conference call and a live Internet webcast along with a slide presentation on Thursday, February 27, 2014 at 8:00 a.m. ET (5:00 a.m. PT) to discuss results for the 2013 fourth quarter and full year.
Valeant Pharmaceuticals International to purchase PreCision Dermatology
M2 - Tue Feb 04, 7:09AM CST
Specialist pharmaceutical company Valeant Pharmaceuticals International Inc (NYSE:VRX)(TSX:VRX), based in Canada, reported on Monday the execution of a definitive agreement to acquire PreCision Dermatology Inc for USD475m in cash.
Concise Analysis of the International Fuel Assemblies for the Nuclear Power Industry - Forecasts to 2020
M2 - Tue Feb 04, 4:13AM CST
Research and Markets (http://www.researchandmarkets.com/research/c6bjcs/fuel_assemblies) has announced the addition of the "Concise Analysis of the International Fuel Assemblies for the Nuclear Power Industry - Forecasts to 2020" report to their offering. "Concise Analysis of the International Fuel Assemblies for the Nuclear Power Industry - Forecasts to 2020", analyzes the market for nuclear fuel assemblies used in commercial nuclear reactors and provides in-depth analysis of the demand in three major regions of the world, including key countries and emerging nuclear nations. The fuel assemblies market analysis provides insights on uranium, conversion, enrichment and fabrication markets. The geographical market analysis is achieved through the division of the global market into three major regions: North America, Europe and Asia-Pacific. Scope - Analysis of the growth of the global nuclear industry and the demand for Fuel Assemblies in various key regions, including Europe, Asia-Pacific and North America. - Analysis of trends in the global nuclear power sector and opportunities in the front end nuclear fuel cycle market. - Nuclear fuel assembly, uranium, conversion, enrichment and fabrication market sizes from 2006 to 2012 and forecast up to 2020 - In-depth analysis and forecasts of the growth potential of the front end nuclear fuel cycle market up to 2020 Reasons to buy - Gain up to date information and analysis relating to global market size of key front-end activities in nuclear fuel cycle - Identify key regions representing potential growth opportunities for the nuclear fuel market - Understand drivers and restraints of front-end activities in nuclear fuel cycle in key countries - Gain information about major players involved in the front end activities of the nuclear fuel cycle industry - Understand potential market opportunities in various geographies and fine tune your business strategy in target locations Key Topics Covered: 1 Table of Contents 2 Introduction 3 Global Fuel Assembly Market Analysis, 2006-2020 4 Fuel Assembly Market Analysis, Europe, 2006-2020 5 Fuel Assembly Market Analysis, North America, 2006-2020 6 Fuel Assembly Market Analysis, Asia-Pacific, 2006-2020 7 Fuel Assembly Market Analysis, Emerging Nuclear Countries, 2006-2020 8 Appendix For more information visit http://www.researchandmarkets.com/research/c6...assemblies
Valeant buying PreCision Dermatology for $475M
AP - Mon Feb 03, 10:05AM CST
NEW YORK (AP) — Valeant Pharmaceuticals is looking to expand its skin care business by buying PreCision Dermatology for $475 million.
Valeant Pharmaceuticals to Acquire Precision Dermatology for $475 Million
CNW Group - Mon Feb 03, 7:01AM CST
Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) today announced that it has entered into a definitive agreement under which Valeant will acquire PreCision Dermatology, Inc. for $475 million in cash, plus an additional $25 million payable upon the achievement of a sales-based milestone. PreCision develops and markets high quality dermatology products with leading products such as Locoid, Hylatopic, Clindagel, and BenzEFoam. PreCision expects to have approximately $130 million in revenue in 2014. The transaction is expected to close in the first half of 2014 and Valeant expects the transaction, once completed, to be immediately accretive to Valeant's cash earnings per share.
